Schrödinger, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SDGR research report →
Range $19 – $19
Price Chart
About the company
Schrödinger, Inc. , together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
- CEO
- Ramy Farid
- IPO
- 2020
- Employees
- 850
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on SDGR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.51B
- P/E
- -34.43
- Fwd P/E
- 57.32
- PEG
- -0.36
- P/S
- 6.66
- P/B
- 6.75
- EV/EBITDA
- -32.37
- Div Yield
- 0.00%
- Gross Margin
- 58.52%
- Op Margin
- -49.64%
- Net Margin
- -22.01%
- ROE
- -18.11%
- ROIC
- -29.00%
Latest fiscal year · YoY change
- Revenue
- $255.87M+23.3%
- Gross Profit
- $142.61M+8.0%
- Op Income
- $-166,896,000
- Net Income
- $-103,265,000+44.8%
- EPS
- $-1.41+45.1%
- OCF Growth
- +108.8%
- FCF Growth
- +107.6%
- 52W High
- $34.00
- 52W Low
- $10.95
- 50D MA
- $27.49
- 200D MA
- $17.71
- Beta
- 1.65
- RSI (14)
- 46
- Avg Volume
- 2.06M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Schrödinger delivered strong Q3 ACV and revenue growth, raised full-year ACV and drug discovery guidance, and said customer interest remains strong across software, Bunsen, predictive tox, and materials science.· November 4, 2026
- Q3 ACV was $44.7 million, up 17% year over year, or 24% excluding contribution ACV.
- Total revenue rose 19% to $64.5 million, led by software revenue of $38.2 million and drug discovery revenue of $24.2 million.
- Hosted software revenue increased 49% to $17.2 million and made up 45% of software revenue, versus 32% a year ago.
- Full-year 2026 ACV guidance was raised to $222 million to $232 million, and drug discovery revenue guidance was lifted to $75 million to $85 million.
- Management said Bunsen, predictive tox, and broader adoption in large pharma, biotech, and materials customers are key growth drivers.
Third-quarter 2026 ACV was $44.7 million, up 17% year over year, or 24% excluding contribution ACV, and trailing four-quarter ACV was $214 million. Total revenue was $64.5 million, up 19% year over year. Software revenue was $38.2 million, including hosted revenue of $17.2 million, up 49%; hosted revenue was 45% of software revenue versus 32% in Q3 2025. Software gross margin was 75% versus 77% in Q3 2025. Drug discovery revenue was $24.2 million versus $13 million a year ago. Total operating expenses were $64 million, down 13% from $74 million, and net loss was $38 million versus $33 million in Q3 2025. Cash and marketable securities ended at $373 million. For full-year 2026, ACV is now expected to be $222 million to $232 million, implying 12% to 17% growth, and drug discovery revenue is expected to be $75 million to $85 million, up from the prior $65 million to $75 million range. Operating expenses are still expected to be less than 2025.
Ramy Farid said the quarter showed sustained commercial momentum and progress toward the company’s long-range goals. He emphasized that customers are responding to proof that the technology works, with strong validation from real-world results and a growing track record across pharma collaborations and co-founded companies. He also highlighted Bunsen as a major strategic step, saying it is already becoming the primary interface for internal workflows and that customer feedback from early access has been very positive.
Richie Jain framed the quarter as a mix of strong ACV growth, a continued shift to hosted licenses, progress in drug discovery, and disciplined spending. He cited $44.7 million of ACV, $64.5 million of revenue, $64 million of operating expenses, a $38 million net loss, and $373 million of cash and marketable securities. He said hosted software transitions temporarily moderate reported revenue because hosted contracts are recognized ratably, and noted each 1% increase in hosted revenue reduces reported revenue by roughly $2 million to $3 million depending on contract length and renewals. He also said 2026 operating expenses are still expected to be below 2025, while the company continues to invest selectively in platform capabilities and growth.
Analysts focused on what is driving customer demand, whether biotech funding conditions are improving, the size and trajectory of material science, monetization of Bunsen, user ramp for Bunsen and predictive tox, and how to think about milestone-driven drug discovery revenue. Management said customers are increasingly convinced the platform works, that biotech funding is much better this year, and that this is contributing to results. On Bunsen, they said engagement is strong but declined to disclose token utilization or pricing details, while noting it should drive more throughput and usage. On predictive tox, they said the technology is aimed earlier in discovery than traditional safety testing and has already contributed to ACV, and they increased the off-target panel to more than 80 proteins.
The call suggested demand is broadening across large pharma, biotech, and materials customers, with management describing strong momentum and better biotech funding conditions. Bunsen and predictive tox appear to be gaining traction, while materials science is framed as a large, early-stage opportunity with room to expand meaningfully over time.
Reported net loss widened to $38 million, software gross margin slipped to 75% from 77% due to the hosted mix shift, and the company said hosted transitions can temporarily pressure reported revenue. Management also said it is too early to quantify Bunsen monetization, token usage, or the material science growth mix, and milestone-based drug discovery revenue remains hard to predict.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.4%
- Shares Outstanding
- 65.91M
- Float Shares
- 57.61M
of shares held by institutions
245 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 10.29M | ▼ 231.38K |
| Gates Foundation Trust | 6.98M | 0 |
| Vanguard Group Inc | 6.46M | ▲ 125.35K |
| Rubric Capital Management LP | 6.40M | ▲ 400.00K |
| Vanguard Portfolio Management LLC | 3.86M | ▲ 67.88K |
| Vanguard Capital Management LLC | 2.68M | ▼ 15.91K |
| Sumitomo Mitsui Trust Group, Inc. | 2.55M | ▼ 153.30K |
| Amova Asset Management Americas, Inc. | 2.55M | ▼ 153.30K |
| Ark Investment Management LLC | 2.37M | ▲ 220.89K |
| State Street Corp | 2.33M | ▲ 31.84K |
| Ubs Am, A Distinct Business Unit Of Ubs Asset Management Americas LLC | 2.22M | ▼ 438.80K |
| Aqr Capital Management LLC | 1.96M | ▲ 1.51M |
Held by 304 ETFs
Biggest fund positions in SDGR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Abel Robert Lorne | other | 21,927 |
| Nov 11, 26 | Abel Robert Lorne | other | 21,927 |
| Nov 11, 26 | Abel Robert Lorne | sell | 21,927 |
| Nov 11, 26 | Abel Robert Lorne | sell | 1,678 |
| Nov 11, 26 | Davie Paul Jonathan | other | 110,600 |
| Nov 11, 26 | Davie Paul Jonathan | other | 18,400 |
| Nov 11, 26 | Davie Paul Jonathan | other | 0 |
| Nov 9, 26 | Tran Yvonne | other | 32,000 |
| Nov 9, 26 | Tran Yvonne | other | 32,000 |
| Nov 9, 26 | Tran Yvonne | sell | 400 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SDGR coverage
Recent articles, reports, and earnings notes.

Iambic Therapeutics IPO Preview: AI Drug Discovery Meets Clinical Risk
Iambic Therapeutics Inc. (NASDAQ: IAM) is expected to list on 2026-10-15, and the IPO has priced at $16.00 per share after offering 9,375,000 shares. The company did not disclose a price range in the materials provided. The bull case is a fast-growing collaboration platform with clinical-stage assets; the bear case is that it still has to prove AI can translate into durable drug wins.

Inside the Nanyang Biologics SPAC Deal: Valuation, Risks, Close
Nanyang Biologics is a Singapore-based AI-driven drug discovery and biotech company going public through a merger with RF Acquisition Corp II (NASDAQ: RFAI). The setup offers a high-upside AI biotech story, but shareholders should watch valuation, redemptions, and dilution closely.

GNQ Insilico's De-SPAC: What Investors Need to Know
GNQ Insilico is a TechBio and precision-medicine company going public through a merger with IB Acquisition Corp. (Nasdaq: IBAC), with the deal originally expected to close in Q3 2026. The bull case is an AI-driven drug discovery platform; the bear case is a small trust, heavy financing dependence, and meaningful dilution risk.
Want a deeper read on SDGR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Schrodinger Eyes Growth From AI Assistant Bunsen and Hosted Software Shift
marketbeat.com · Nov 13
Schrödinger, Inc. (SDGR) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
Critical Analysis: Schrodinger (NASDAQ:SDGR) versus Health In Tech (NASDAQ:HIT)
defenseworld.net · Nov 9
Schrödinger, Inc. (SDGR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
What Schrodinger (SDGR) Said on Its Q3 Earnings Call
marketbeat.com · Nov 4
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 4
Schrödinger Reports Third Quarter 2026 Financial Results
businesswire.com · Nov 4
Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline
zacks.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.